Risk of synchronous and second primary malignancies in transplant-ineligible patients with multiple myeloma treated with lenalidomide. - Systchenko T; Nsiala L; Bobin A; Gardeney H; Motard C; Olivier G; Borde F; Corby A; Roul C; Fleck E; Denis G; Dieval C; et al. (Blood advances, 2025)